ARA-290
Cibinetide
Erythropoietin-derived peptide for nerve repair and anti-inflammatory effects.
Mechanism of Action
Activates innate repair receptor (IRR) to reduce inflammation and promote tissue/nerve healing.
Key Benefits
- Relieves neuropathic pain
- Improves small-fiber neuropathy
- Tissue protection
Common Uses
What to Expect
Onset
Pain relief begins within 3–7 days; neuropathy improvement builds over 2–4 weeks
Duration
Effects build over the full 28-day protocol; improvements can persist after completing the cycle
What Users Report
- Gradual reduction in neuropathic pain — burning, tingling, and numbness slowly improve
- Improved sensation in previously affected areas; some describe it as 'nerves waking up'
- Subtle but meaningful improvement in quality of life as chronic pain diminishes
- Anti-inflammatory effects noticeable over weeks — general reduction in systemic inflammation
- Generally very well tolerated with few subjective side effects
- Best results seen in small fiber neuropathy; the improvement is functional and measurable
- Effects are gradual and cumulative — patience is required through the full 28-day protocol
Typical Timeline
Days 1–7: Early pain relief begins; nerve healing process initiated. Days 7–14: Neuropathic symptoms start improving noticeably. Days 14–28: Progressive nerve repair; significant reduction in pain and improved sensation. Post-cycle: Improvements often persist as nerve regeneration continues.
Side Effects
- Generally well tolerated
Dosage Protocol
2–4 mg daily via subcutaneous injection for 28 days (clinical trial protocols). Some maintenance: every other day. Titrate under physician supervision for neuropathy.
Always consult a physician before starting any peptide protocol.
Administration
Subcutaneous injection
FDA Status
Investigational / research (Phase 2 completed)
Stacks Well With
- BPC-157
- KPV